DermTech Inc (DMTK)
DermTech is a molecular diagnostic company developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Co.'s focus is skin cancer. Co. provides the DermTech Melanoma Test for the early detection of melanoma and is developing a product for non-melanoma skin cancer. Co. is also working on products to assess precancerous genomic changes associated with sun UV exposure to the skin. Co. has additional skin cancer product offerings, including for non-melanoma skin cancers (basal cell and squamous cell cancers), under development.
Company Name: |
DermTech Inc |
Website: |
www.dermtech.com |
Sector: |
Biotechnology |
Number of ETFs Holding DMTK: |
3 |
Total Market Value Held by ETFs: |
$828204 |
Total Market Capitalization: |
$21.00M |
% of Market Cap. Held by ETFs: |
3.94% |
|
|
April 27, 2024 12:48 PM Eastern
Hold (2.50 out of 4)
5th percentile
|
|